
AxoGen AXGN
$ 33.22
1.87%
Quarterly report 2025-Q2
added 08-05-2025
AxoGen Interest Expense 2011-2026 | AXGN
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense AxoGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -199 K | -437 K | -230 K | 1.36 M | 1.05 M | 40 K | 1.21 M | 2.22 M | 5.39 M | 3.99 M | 6.81 M | 4.82 M | 1.39 M | 1.09 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.81 M | -437 K | 2.04 M |
Quarterly Interest Expense AxoGen
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 179 K | -37 K | - | -48 K | 1 K | -107 K | - | -6 K | -277 K | 16 K | - | 61 K | 249 K | 354 K | - | 417 K | 565 K | 444 K | - | 397 K | 31 K | 31 K | - | -7 K | 11 K | 14 K | - | -16 K | 544 K | 586 K | - | 578 K | 554 K | 508 K | 5.39 M | 5.39 M | 1.16 M | 5.39 M | - | 1.04 M | 1.02 M | 995 K | - | 1.38 M | 1.39 M | 1.19 M | - | 1.21 M | 1.22 M | 1.07 M | - | 145 K | 125 K | 125 K | - | 318 K | 406 K | 203 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.39 M | -277 K | 760 K |
Interest Expense of other stocks in the Medical devices industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Allied Healthcare Products
AHPI
|
191 K | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
4.67 M | - | - | $ 475 M | ||
|
Axonics Modulation Technologies
AXNX
|
-2.43 M | - | - | $ 3.31 B | ||
|
Acutus Medical
AFIB
|
5.66 M | - | -26.83 % | $ 2.62 M | ||
|
Aziyo Biologics
AZYO
|
5.8 M | - | 1.37 % | $ 20.5 M | ||
|
Cognyte Software Ltd.
CGNT
|
-1.61 M | $ 7.01 | 2.04 % | $ 503 M | ||
|
Apyx Medical Corporation
APYX
|
2.48 M | $ 3.76 | -1.7 % | $ 130 M | ||
|
Alphatec Holdings
ATEC
|
24.9 M | $ 13.29 | 1.41 % | $ 1.9 B | ||
|
BIOLASE
BIOL
|
-1 K | - | -13.19 % | $ 166 K | ||
|
Bio-Rad Laboratories
BIO
|
48.9 M | $ 255.19 | -12.51 % | $ 7.2 B | ||
|
Conformis
CFMS
|
2.02 M | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
-38.2 M | $ 36.35 | -3.09 % | $ 5.42 K | ||
|
BioSig Technologies
BSGM
|
23 K | - | 37.08 % | $ 85.7 M | ||
|
CONMED Corporation
CNMD
|
37.3 M | $ 41.59 | -0.28 % | $ 1.28 B | ||
|
Boston Scientific Corporation
BSX
|
305 M | $ 74.77 | 0.88 % | $ 110 B | ||
|
Abbott Laboratories
ABT
|
376 M | $ 112.22 | 0.66 % | $ 195 B | ||
|
Cardiovascular Systems
CSII
|
1.63 M | - | 0.15 % | $ 844 M | ||
|
EDAP TMS S.A.
EDAP
|
232 K | $ 4.8 | 0.63 % | $ 179 M | ||
|
Delcath Systems
DCTH
|
-30 K | $ 9.25 | 1.43 % | $ 264 M | ||
|
Cutera
CUTR
|
-244 K | - | -10.19 % | $ 1.99 M | ||
|
ClearPoint Neuro
CLPT
|
-40 K | $ 13.44 | 3.07 % | $ 363 M | ||
|
Electromed
ELMD
|
78 K | $ 24.2 | 3.82 % | $ 205 M | ||
|
Dynatronics Corporation
DYNT
|
410 K | - | 14.99 % | $ 929 K | ||
|
Neovasc
NVCN
|
133 K | - | - | $ 111 M | ||
|
Eargo
EAR
|
549 K | - | - | $ 10.2 M | ||
|
Inogen
INGN
|
850 K | $ 5.71 | -1.38 % | $ 135 M | ||
|
IRadimed Corporation
IRMD
|
164 K | $ 99.81 | -0.03 % | $ 1.26 B | ||
|
Integer Holdings Corporation
ITGR
|
-3.52 M | $ 85.46 | 0.23 % | $ 2.87 B | ||
|
Second Sight Medical Products
EYES
|
1.19 M | - | -0.97 % | $ 54.4 M | ||
|
Penumbra
PEN
|
-682 K | $ 339.82 | 0.32 % | $ 13.1 B | ||
|
Avinger
AVGR
|
1.72 M | - | -20.74 % | $ 369 K | ||
|
FONAR Corporation
FONR
|
347 K | $ 18.55 | 0.05 % | $ 122 M | ||
|
Pulmonx Corporation
LUNG
|
256 K | $ 1.47 | 3.17 % | $ 57.5 M | ||
|
Globus Medical
GMED
|
2.2 M | $ 87.89 | 0.76 % | $ 11.9 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
3.94 M | $ 11.29 | 4.46 % | $ 869 M | ||
|
Myomo
MYO
|
21.1 K | $ 0.82 | 0.41 % | $ 5.78 M | ||
|
Establishment Labs Holdings
ESTA
|
-15.3 M | $ 75.22 | 2.28 % | $ 2.12 B |